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Background and aims: The UK Simon Broome (SB) familial hypercholesterolaemia (FH) register previously re-
ported 3-fold higher standardised mortality ratio for cardiovascular disease (CVD) in women compared to men 
from 2009 to 2015. Here we examined sex differences in CVD morbidity in FH by national linkage of the SB 
register with Hospital Episode Statistics (HES). 
Methods: Of 3553 FH individuals in the SB register (aged 20–79 years at registration), 2988 (52.5% women) had 
linked HES records. Standardised Morbidity Ratios (SMbR) compared to an age and sex-matched UK general 
practice population were calculated [95% confidence intervals] for first CVD hospitalisation in HES (a composite 
of coronary heart disease (CHD), myocardial infarction (MI), stable or unstable angina, stroke, TIA, peripheral 
vascular disease (PVD), heart failure, coronary revascularisation interventions). 
Results: At registration, men had significantly (p < 0.001) higher prevalence of previous CHD (24.8% vs 17.6%), 
previous MI (13.2% vs 6.3%), and were commenced on lipid-lowering treatment at a younger age than women 
(37.5 years vs 42.3 years). The SMbR for composite CVD was 6.83 (6.33–7.37) in men and 7.55 (6.99–8.15) in 
women. In individuals aged 30–50 years, SMbR in women was 50% higher than in men (15.04 [12.98–17.42] vs 
10.03 [9.01–11.17]). In individuals >50 years, SMbR was 33% higher in women than men (6.11 [5.57–6.70] vs 
4.59 [4.08–5.15]). 
Conclusions: Excess CVD morbidity due to FH remains markedly elevated in women at all ages, but especially 
those aged 30–50 years. This highlights the need for earlier diagnosis and optimisation of lipid-lowering risk 
factor management for all FH patients, with particular attention to young women with FH.   
1. Introduction 
Familial hypercholesterolaemia is an autosomal dominant disorder 
characterised by lifelong elevated plasma levels of low-density lipo-
protein (LDL) cholesterol, which when untreated, leads to increased risk 
of coronary heart disease (CHD) and premature death [1]. More 
recently, individuals with FH phenotype in primary care have been 
shown to have a greatly increased risk of not only CHD, but also stroke 
and peripheral vascular disease (PVD) [2]. Heterozygous FH affects 1 in 
250 to 1 in 300 of the general population but the majority of these 
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individuals are undiagnosed [3,4]. If untreated, men with FH have a 
50% risk of fatal or non-fatal CHD by age 50 years and women have a 
30% risk by age 60 years [5]. 
In early studies of FH in the pre-statin era, CHD mortality was shown 
to be highest in the 20–39 year age group and reduced with increasing 
age [6]. Previous studies of the UK Simon Broome register examined 
changes in CHD mortality in FH patients both before and after the 
routine use of statins, and found that while there was a significant 
reduction in CHD mortality in men over time, excess mortality persisted 
in women [7], such that excess CHD mortality was 3-fold higher in 
women than men in the period from 2009 to 2015 [7]. These previous 
studies were limited to only coronary disease mortality outcomes in this 
patient population. As individuals with FH are now living longer due to 
effective lipid lowering therapies and coronary interventions [8], 
morbidity across a range of CVD outcomes now need to be examined. By 
linking records of Simon Broome register participants with their sec-
ondary care records from hospital episode statistics, we have now 
created the longest prospective cohort of FH patients known 
internationally. 
This study evaluated the long-term CVD outcomes of individuals 
with heterozygous FH, and investigated any potential sex differences in 
cardiovascular disease morbidity associated with FH. 
2. Materials and methods 
2.1. Data source and baseline measures 
The Simon Broome register includes individuals with FH recruited 
from 21 participating lipid clinics in the United Kingdom, to which they 
had been referred by either their general practitioners or hospital spe-
cialists. Recruitment of patients into the register began in 1980, and 
methods have been described previously [6,7,9]. Information recorded 
on registration into the Simon Broome register include individuals’ 
baseline demographic and clinical characteristics such as age, smoking 
status, alcohol consumption, past medical history, medication history 
including use of lipid-lowering, antihypertensive and diabetic treat-
ments, family history as well as clinical examination findings such as 
blood pressure, body mass index, tendon xanthomas, xanthelasma and 
arcus cornealis. A fasting blood specimen taken at the registration visit 
determined serum total cholesterol, triglycerides and high density li-
poprotein [6,7,9]. Serum low density lipoprotein cholesterol (LDL-C) 
concentrations were calculated using the Friedewald equation [10]. 
Lipoprotein (a) (Lp(a)) concentration was measured in a single labora-
tory using a previously described method [11]. Patients were classified 
as having either Simon Broome Definite FH or Possible FH using pre-
viously published criteria [6,7,9]. Registered patients in the Simon 
Broome register were linked with the National Health Service Central 
Registry, which is part of the Office for National Statistics, for ascer-
tainment of death records including underlying cause and date of death. 
For the current analysis, patients’ records have been linked to Hospital 
Episodes Statistics (HES) for ascertainment of secondary care inpatient 
morbidity data including admissions for cardiovascular disease. All pa-
tients were followed up from the date of their SB registration until their 
first hospitalisation for cardiovascular disease, date of death, emi-
gration/loss to follow-up or last date of data collection, whichever 
occurred first. All patients gave informed consent for inclusion in the 
Simon Broome Register. The study received approval from the local 
ethics committee of each participating centre, and approvals for 
obtaining the linked hospital data was obtained by the NHS digital 
(DARS ref: NIC-115405) and Confidentiality Advisory Committee (CAG 
ref: 18/CAG/0007). The overall study obtained ethical approval from 
the NHS Health Research Authority (IRAS ref: 214219). 
2.2. Cardiovascular disease outcome measures 
Incident cardiovascular disease (CVD) was defined as the first hos-
pital admission recorded in HES for coronary heart disease (CHD), 
myocardial infarction (MI), angina (stable or unstable), stroke, transient 
ischaemic attack (TIA), peripheral vascular disease (PVD), heart failure, 
or coronary revascularisation interventions such as percutaneous coro-
nary interventions (PCI) or coronary artery bypass graft (CABG). Car-
diovascular disease outcomes were identified from HES using the 
relevant ICD-10 and OPCS codes (shown in Supplementary Data). 
2.3. Statistical analyses 
Baseline characteristics of patients in the Simon Broome register 
were assessed, and these were reported as proportions, mean (standard 
deviation) and median (interquartile range) for categorical, continuous 
normally-distributed and continuous non-normally distributed vari-
ables, respectively. Appropriate statistical tests such as chi-squared, t- 
tests and Mann-Whitney U tests were used to assess differences in cat-
egorical and continuous variables, between males and females. Inci-
dence rates of composite CVD outcomes were assessed for all SB patients 
as well as within pre-defined patient subgroups, and Cox-proportional 
hazard models estimated hazards ratios for CVD. We determined the 
observed number of incident CVD events per person-years of follow-up, 
stratified by sex and age-groups (<30 years, 30 to >50 years and in the 
over 50 year age-groups). Standardised morbidity ratios (SMbR) were 
calculated using indirect standardisation, with age and sex-specific CVD 
incidence rates of the UK primary care non-FH population, as reference 
rates [2]. We calculated the expected number of CVD events as the 
number of person-years of follow-up in the SB cohort multiplied by the 
incidence rate for the comparable age-group and sex in the reference 
population. Standardised morbidity ratios (SMbR) were computed as the 
observed number of CVD events divided by the expected number of 
events:   
The 95% confidence intervals of the SMbR were derived using an 
error factor (EF), with the equation: 95% CI = SMbR / EF to SMbR × EF, 
where EF = exp (1.96 / √di). 
SMbR was estimated for both composite CVD and constituent CVD 
outcomes. We conducted the primary analyses on all eligible individuals 
in the Simon Broome register, with or without a history of CVD. To 
evaluate the impact of having a previous history of CVD, we conducted 
sensitivity analyses by restricting the population to a subset of patients 
who had no history of previous CVD at the time of registration. 
Considering that secondary care records in HES only became available 
after 1 April 1997, a further sensitivity analysis was done with analyses 
restricted to only those individuals with registration dates in Simon 
Broome on or after 1 April 1997. All analyses were conducted using 





observed number of CVD events in the SB population
expected number of CVD events if the age − sex specific rates were the same as the
reference population   
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3. Results 
A total of 3553 subjects in the Simon Broome (SB) database were 
recruited from participating lipid clinics between 1 January 1980 and 20 
December 2010. Of these, 2988 (84%) had linked HES admitted patient 
care records, and comprised the final study cohort. Individuals without 
linked HES records had comparable baseline demographic characteris-
tics to those with linked data, but a higher proportion of them had re-
cords of previous history of CVD. A comparison of baseline 
characteristics between individuals with and without linked HES re-
cords is shown in Supplementary Table 1. 
The characteristics of the study population, at the time of registration 
into the Simon Broome register, are shown in Table 1. Of the cohort, 
1418 (47.5%) were male. Compared to men, women were 5 years older 
at registration and 4.8 years older at the time of commencing lipid 
lowering treatment (LLT). While women had a slightly lower BMI than 
men, their mean untreated total cholesterol concentration was signifi-
cantly higher, but median triglyceride concentration was significantly 
lower. Consumption of alcohol was significantly higher in men than 
women but significantly fewer women reported ever smoking, while the 
prevalence of current smoking was similar in men and women. Fewer 
women reported a prior history of CVD than men, with significant dif-
ference in myocardial infarction (MI), CHD and previous revascular-
isation, and women having had their first MI 8 years later than men. 
While significantly more women than men had a history of hyperten-
sion, the prevalence of type 2 diabetes was similar in men and women, 
and although low overall, was similar to the prevalence of type 2 
diabetes in the UK general population during the period of recruitment 
of the patient cohort [12]. Only 21.8% of the SB cohort had measures of 
Lp(a) at registration, but there was no statistically significant difference 
between these measures in males and females. Genetic test results were 
only available for 599 patients (20% of the study population) and an 
FH-causing variant was identified in 399 (67% of those tested), with no 
significant difference between males and females. Overall, women on 
the SB register had a better CVD risk factor profile, but a later age at FH 
diagnosis and commencement of LLT. 
3.1. Cardiovascular disease outcomes 
Admitted patient care records from HES were available from April 
1997 to March 2018. The median follow-up for patients in the SB reg-
ister was 18.1 years (IQR 11.4–23.9), constituting 52,000 person-years 
of follow-up. Over this period, there were 1327 CVD-related hospital 
admissions. As shown in Table 2, the overall incidence rate for any CVD 
event in the SB patients was 25.47 (95% CI 24.14–26.88) per 1000 p- 
years follow-up. Incidence rates were lower in women, and compared to 
men, women had an adjusted hazard ratio (HR) of 0.65 (0.58–0.73). As 
expected, incidence rates and hazards ratio for CVD increased steeply 
with increasing age, with incidence rates ranging from 6.31 (5.12–7.77) 
in those less than 30 years at registration to 77.35 (59.67–100.28) in 
those over 70 years. The median age at first CVD-related hospital 
admission for CVD was 60.6 years (IQR 51.5–69.5) in men, and 70.0 
years (IQR 60.0–77.6) in women. There were very few individuals with 
FH genetic test results, so statistically significant difference in hazard 
Table 1 
Baseline characteristics of subjects with FH in the Simon Broome register (n = 2988).    
Male n (%) 
1418 (47.46) 
Female n (%) 
1570 (52.54) 
p-valuea 
Age at registration (years) mean (SD) 41.1 (15.0) 46.1 (16.8) <0.0001 
BMI at registration (Kg/m2) mean (SD) 25.17 (4.1) 24.78 (5.2) 0.0343 
Follow-up (years) median (IQR) 17.93 (11.17–23.98) 18.15 (11.59–23.73) 0.5993 
FH diagnosis type  n = 1418 n = 1570  
Definite FH n (%) 770 (54.3) 814 (51.9) 0.179 
Possible FH  648 (45.7) 756 (48.1)  
Age started on LLT (years) mean (SD) 37.5 (14.7) 42.3 (17.0) <0.0001 
Pre-treatment cholesterol (mmol/l) mean (SD) 9.4 (2.8) 9.7 (2.0) 0.0136 
Pre-treatment triglyceride (mmol/l) median (IQR) 1.8 (1.2–2.7) 1.4 (1.0–2.2) <0.0001 
Pre-treatment lipoprotein Lp(a) (mg/dl) median (IQR) 29 (10–63), n = 314 25 (11–70), n = 339 0.9927 
Alcohol consumption (units/week) median (IQR) 10 (1–20) 2 (0–9) 0.0001 
Cigarette smoke exposure 
Ever smoked cigarette (yes) n (%) 638 (45.0%, n = 1418) 605 (38.6%, n = 1568) 0.001 
Current cigarette smoker (yes)  224 (16.0%, n = 1404) 293 (18.8%, n = 1556) 0.116 
History of previous cardiovascular disease 
Angina n (%) 250 (17.8%, n = 1403) 226 (14.5%, n = 1554) 0.091 
Myocardial infarction  187 (13.2%, n = 1418) 99 (6.31%, n = 1570) <0.0001 
Coronary heart disease (yes)  352 (24.8%, n = 1418) 276 (17.6%, n = 1570) <0.0001 
Stroke (Yes)  10 (0.7%, n = 1404) 20 (1.3%, n = 1558) 0.173 
Transient ischaemic attack  13 (1.3%, n = 1027) 18 (1.5%, n = 1168) 0.254 
History of claudication  38 (2.7%, n = 1402) 49 (3.2, n = 1556) 0.790 
Previous revascularisation (Angioplasty/CABG)  174 (17.0%, n = 1025) 96 (8.3%, n = 1161) <0.0001 
Age at first MI (years) median (IQR) 43 (37–49) 51 (44–58.5) 0.0001 
History of hypertension n (%) 111 (10.9%, n = 1021) 196 (16.9%, n = 1162) <0.0001 
History of diabetes n (%) 20 (1.4%, n = 1418) 19 (1.2%, n = 1570) 0.718 
Use of other medications 
Beta-blockers n (%) 117 (11.4%, n = 1028) 148 (12.7%, n = 1168) 0.644 
Ace-inhibitors  39 (6.6%, n = 587) 54 (7.8%, n = 697) 0.610 
Anti-platelet medication  257 (18.1%, n = 1418) 234 (14.9%, n = 1570) 0.010 
Anticoagulant medication  9 (1.5%, n = 587) 10 (1.4%, n = 697) 0.830 
Other antihypertensive medications  49 (4.8%, n = 1027) 74 (6.3%, n = 1168) 0.274 
Type of FH mutation  n = 295 n = 304  
LDL-receptor n (%) 178 (60.3%) 193 (63.5%) 0.416 
Apo-B  10 (3.4%) 13 (4.3%)  
PCSK9  4 (1.4%) 1 (0.3%)  
None  103 (34.9%) 97 (31.9%)  
Tests of significance for categorical variables were derived using the Pearson’s χ2 test. 
a Independent t-test was used for comparison between continuous variables with normal distribution, and Mann-Whitney U test for variables with non-normal 
distribution. 
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ratios for CVD could not be determined between the different FH- 
mutation carrier groups (data not shown). As expected, the CVD inci-
dence rate was 4.5 fold higher in those with a previous history of CVD on 
registration, with an age and sex adjusted HR of 3.45 (3.06–3.89). 
Table 3 shows the observed number of CVD events across different 
age-groups in men and women in the SB register, as well as the number 
of CVD events that would be expected if these individuals had the same 
age- and sex-specific CVD incidence rates as the general practice pop-
ulation of individuals without FH. The overall standardised morbidity 
ratio (SMbR) among individuals with FH in the SB register was 7.17 
(6.79–7.56). In both sexes, SMbR decreased with advancing age such 
that the highest excess CVD morbidity was in those younger than 30 
years, and the lowest was in those over 50 years. Women with FH were 
observed to have larger excess CVD morbidity than men (7.55 
(6.99–8.15) vs 6.83 (6.33–7.37) respectively). There were substantially 
significant sex differences in SMbR in patients aged 30–50 years and 
those older than 50 years (Fig. 1). These differences were most marked 
in the 30–50 year age group such that women had a 50% higher SMbR 
than men of the same age group (15.04 (12.98–17.42) vs 10.03 
(9.01–11.17). In those older than 50 years, SMbR was 33% higher in 
women than men (6.11 (5.57–6.70) vs 4.59 (4.08–5.15) respectively). 
The median age at first hospitalisation for CVD in males and females 
with FH, by age-group at time of Simon Broome registration, is shown in 
Supplemental Table 2. 
On separate analyses of subtypes of the first CVD event, the SMbR for 
all subtypes were found to be higher in women than men (Fig. 2). The 
SMbR (95% CI) for CHD was substantially higher in women than men in 
the 30–50 year age group (19.66 (16.78–23.04) vs 12.54 (11.22–14.01)) 
and those over 50 years (7.65 (6.90–8.48) vs 5.82 (5.14–6.59)). Simi-
larly, women had higher SMbR for PVD than men in the 30–50 year age 
group (16.16 (11.85–22.03) vs 8.18 (6.26–10.68)) and in the over 50 
year age group (8.44 (7.02–10.14) vs 4.67 (3.68–5.93)). Higher SMbR 
for stroke was observed for women than men, but this was only in those 
aged over 50 years (5.66 (4.78–6.69) vs 2.83 (2.17–3.69)). In all CVD 
subtypes, the SMbR did not differ markedly between men and women 
with FH who were aged younger than 30 years (data are shown in 
Supplementary Table 3). 
3.2. Sensitivity analyses 
On restricting all analyses to only the subset of FH patients who had 
no history of previous CVD at the time of registration into the Simon 
Broome register, as expected, SMbR for men and women of all age 
groups were lower than estimates from the whole cohort. There were 
however similar findings of higher SMbR for CVD in women than men in 
the 30–50 year group (10.68 (8.88–12.86) vs 7.06 (6.12–8.14)) and in 
those aged 50 years and over (4.11 (3.61–4.68) vs 2.73 (2.26–3.31)) 
(Supplementary Table 4). 
Further sensitivity analyses, which included only individuals who 
registered in the Simon Broome on or after the 1 April 1997, when 
Table 2 





Persons_years of follow- 
up 
Incidence rate (95% CI) of 
CVD 
Unadjusted hazards ratio for 
CVD 
Adjusted HR for age and 
sexb 
All subjects in SB 
register 
2988 1327 52,090 25.47 (24.14–26.88)   
Sex 
Male 1418 669 24,630 27.17 (25.18–29.30) 1.00 1.00 
Female 1570 658 27,470 23.96 (22.19–25.86) 0.89 (0.80–0.99) 0.65 (0.58–0.73) 
Age at registration (years) 
<30 614 89 14,100 6.31 (5.12–7.77) 1.00 1.00 
30 - <40 568 204 10,950 18.64 (16.25–21.38) 3.38 (2.63–4.34) 3.32 (2.59–4.26) 
40 - <50 620 305 10,770 28.31 (25.30–31.67) 5.50 (4.34–6.98) 5.44 (4.29–6.90) 
50 - <60 674 379 10,440 36.29 (32.81–40.13) 8.09 (6.40–10.23) 8.54 (6.75–10.80) 
60 - <70 425 293 5090 57.51 (51.29–64.49) 16.21 (12.68–20.74) 17.88 (13.96–22.91) 
>70 87 57 740 77.35 (59.67–100.28) 26.16 (18.58–36.84) 29.90 (21.18–42.20) 
FH diagnosis type 
Definite FH 1584 726 28,150 25.79 (23.99–27.74) 1.00 1.00 
Possible FH 1404 601 23,950 25.10 (23.17–27.18) 1.00 (0.90–1.12) 0.84 (0.75–0.93) 
Past history of CVD 
No past history of 
CVD 
2290 720 43,900 16.40 (15.25–17.64) 1.00 1.00 
Past history of CVD 698 607 8190 74.10 (68.44–80.24) 5.90 (5.27–6.60) 3.45 (3.06–3.89) 
Previous CVD includes previous CHD, MI, coronary revascularisation interventions (coronary angioplasty or CABG), stroke, TIA, intermittent claudication. 
b HR for CVD in males and females was adjusted for age only, and HR for CVD in different age categories was adjusted for sex only. 
Table 3 
Observed and expected number of CVD events in men and women with FH in the Simon Broome register.   








Standardised morbidity ratio (95% 
CI) 
Males 
<30 years 6942 56 8.07 (6.21–10.48) 3.47 16.13 (12.42–20.96) 
30 to <50 years 12,174 331 27.19 (24.41–30.28) 32.99 10.03 (9.01–11.17) 
50 years 5510 282 51.18 (45.54–57.51) 61.49 4.59 (4.08–5.15) 
Total (men) 24,627 669 27.17 (25.18–29.30) 97.96 6.83 (6.33–7.37) 
Females 
<30 years 7157 33 4.61 (3.28–6.49) 2.15 15.37 (10.93–21.62) 
30 to <50 years 9546 178 18.65 (16.10–21.60) 11.84 15.04 (12.98–17.42) 
>50 years 10,765 447 41.52 (37.85–45.56) 73.20 6.11 (5.57–6.70) 
Total (women) 27,468 658 23.96 (22.19–25.86) 87.18 7.55 (6.99–8.15) 
Overall 52,094 1327 25.47 (24.14–26.88) 185.14 7.17 (6.79–7.56)  
a Expected CVD events derived by applying age and sex-specific CVD incidence rates in the UK general practice population of non-FH subjects [2], to the number of 
person-years of follow-up. 
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secondary care records in HES were available, found that similar to re-
sults of analyses of the whole cohort, SMbR for CVD was higher in 
women than men. Unlike findings from the whole cohort, the higher 
SMbR in women compared to men was most marked in those younger 
than 30 years. Due to the small sample size and few observed number of 
CVD events in this subgroup of patients, there was insufficient power to 
detect statistically significant measures of effect, and so the 95% con-
fidence intervals for these estimates were very wide (Supplementary 
Table 5). 
4. Discussion 
4.1. Main findings 
This study of the 36 year prospective cohort of patients with FH has 
shown that patients living with FH had excess rates of hospitalisations 
for CVD across all age groups, compared to the general population of 
individuals without FH. As expected, the incidence rate of CVD was 
lowest in those who were under 30 years at time of registration, and this 
increased with increasing age. However, compared to the general non- 
FH population, excess CVD morbidity due to FH, was highest in the 
youngest age group and decreased with increasing age. Overall, SMbR 
was 16-fold higher in FH patients than the general population in those 
under 30 years, and was 5-fold higher in those over 50 years. At 
registration, men with FH had higher prevalence of CVD risk factors, and 
were diagnosed and commenced on lipid-lowering treatment earlier 
than women with FH. Although the absolute incidence rate of CVD 
associated with FH was higher in men than women across all age groups, 
excess CVD morbidity compared to the general population without FH 
was substantially higher in women than men aged 30 years and over, 
and this was most marked in those aged 30–50 years at time of regis-
tration in Simon Broome. 
4.2. Strengths and limitations 
The Simon Broome register is a well-established FH register, and 
until now it had been only linked to the Office for National Statistics for 
ascertainment of death records. This study used a new national linkage 
of patient records in the register with their secondary care records in 
hospital episode statistics, providing an 18-year follow-up, and making 
this the longest prospective study of FH in the world. To our knowledge, 
this study is the first to investigate long-term secondary care outcomes in 
a registry cohort of patients with FH. Over 84% of patients in the Simon 
Broome register had linked secondary care records from HES, which 
enabled comprehensive and robust ascertainment of different CVD 
outcomes, as well as interventions such as coronary interventions. We 
were also able to quantify the rates of coronary revascularisations in FH 
patients, which to date, has largely been understudied [13]. 
Fig. 1. Standardised morbidity ratios for composite CVD in men and women with familial hypercholesterolaemia in the Simon Broome register.  
Fig. 2. Standardised morbidity ratios for coronary heart disease, stroke, and peripheral vascular disease in males and females with familial hypercholesterolaemia.  
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Study limitations include the lack of data on lipid-lowering treat-
ments or more recent LDL-cholesterol concentrations beyond the time of 
SB registration, which could potentially explain the observed differences 
in CVD outcomes in men and women. It had however been shown in the 
2010 survey of FH management in adults attending UK lipid clinics [14] 
that 86% of patients were on statin treatment, with 40% additionally 
being treated with Ezetimibe; which was associated with a median 
LDL-cholesterol reduction of 47% from baseline, at patients’ third lipid 
clinic visit [14]. As patients in our SB register cohort were recruited from 
UK lipid clinics, it is reasonable to assume that the proportion on 
lipid-lowering treatments will be consistent with findings from the 
audit, as well as more recent national guideline recommendations [15]. 
Over 50% of men and women in the SB register fulfilled the “definite 
FH” criteria, as such there may be a degree of selection bias towards 
those with more severe FH phenotype. We had no data on obstetric 
outcomes of women in this study, and so were unable to ascertain 
whether CVD outcomes differed between women with documented 
obstetric admissions who may have discontinued statin therapy during 
pregnancy and lactation, and those with fewer or no documented ob-
stetric admissions. Also, electronically linked hospital records were only 
available from 1997 onwards, and therefore in participants who were 
registered prior to this date, there is likely under-ascertainment of CVD 
outcomes. Although our expectations are that any under-ascertainment 
of CVD outcomes are conservative in nature and not likely to affect 
males and females differently, we conducted a sensitivity analyses of 
those individuals whose date of registration in SB register was after the 
inception of HES on 1 April 1997. Although the finding of higher SMbR 
for CVD in women compared to men was broadly similar to findings 
from the main analyses, statistical significance could not be determined 
due to the small sample size of this patient subgroup. 
A final limitation of the study is that, because DNA testing is not 
widely available in the UK, genetic testing was only done for 20% of the 
SB cohort, and only 13% of the total cohort had a DNA confirmed 
diagnosis. Therefore, there were too few mutation carriers to enable a 
statistically robust assessment of the relationship between mutation 
positive status (gene mutation) and CVD morbidity. However, all pa-
tients in the SB register were from specialist clinics and have clearly 
defined clinical phenotypes of FH. 
4.3. Comparison with existing literature 
Our study finding that excess CVD morbidity due to FH was highest 
in those younger than 30 years, and declined with advancing age, builds 
on previous research from the Simon Broome register, which reported 
the highest excess mortality from CHD before the age of 40 [6]. 
Consistent with our study findings, individuals in a Norwegian FH reg-
istry had the highest excess risk of acute MI and CHD in those aged 
25–39 years [16]. 
The substantially higher SMbR for composite CVD in women than 
men, in the 30 to 50, and over 50 age groups, is a novel finding of 
considerable clinical significance. Although a study of the general 
population of adults with phenotypic FH in the United States had shown 
that age-based acceleration of CHD risk was greater for women than men 
[17], the study did not explore sex-differences in the increased risk of 
composite CVD outcomes associated with FH. It had previously been 
shown in the Simon Broome register that excess CHD deaths associated 
with FH were 3-fold higher in women than men for the period 2009 to 
2015 [7]. While excess CHD deaths declined in men comparing the 
period before and after the routine use of statins, no corresponding 
decline was observed over time in women [7]. There are several possible 
explanations which may underlie our study finding of higher excess CVD 
morbidity in women compared to men. We found that the mean ages for 
commencing lipid-lowering treatment in men and women were 37.5 
years and 42.3 years, respectively. While women typically develop CVD 
at a later age than men, the risk of CVD is often underestimated in 
women due to the misperception that females are ‘protected’ against 
CVD before the menopause [18]. While premenopausal women have a 
less pro-atherogenic plasma lipid profile than men, specifically greater 
high-density lipoprotein (HDL) and lower LDL-cholesterol than men of 
the same age [19], a study of children and adolescents with untreated 
FH suggests that the cholesterol burden with untreated FH is signifi-
cantly higher in girls than boys [20]. These factors are likely to 
contribute to the greater excess CVD burden in women with FH 
compared to women without FH. Since statins are not recommended 
during pregnancy and breastfeeding, women with children are also 
likely to have experienced one or more interruptions of 2–3 years in 
their lipid lowering therapy and thus to have accumulated a greater 
“LDL-C burden” than men of the same age. Despite the greater CVD 
burden observed in women with FH compared to non-FH women, the 
incidence of CVD in individuals with FH remained lower in women than 
men across all age groups, suggesting that women may still retain some 
relative protection from CVD. 
Statin prescribing rates have been shown to be lower in women than 
men in the general population [21], with numerous studies reporting 
that women in general are less likely to be prescribed evidence-based 
guidelines, and less aggressively treated in cardiology care for both 
primary [22] and secondary prevention [23]. Studies in the FH popu-
lation have also demonstrated greater prescribing of more potent 
lipid-lowering therapy in men than women with FH, suggesting that FH 
treatment may be suboptimal in women [24,25]. This is consistent with 
findings from the survey of FH patients in UK lipid clinics, which showed 
that more men than women attained the FH treatment target of 50% or 
more reduction in baseline LDL-C [14]. In addition, gender was not 
found to be associated with adherence to statin therapy in a study of 
patients with FH [26]. 
4.4. Clinical implications and conclusion 
This study finding of significantly higher risk of CVD in all age groups 
of patients in this registry-based cohort, compared to the general pop-
ulation, emphasizes the importance of early diagnosis and treatment of 
FH. Strategies to identify individuals with FH at a young age, before the 
development of significant coronary atherosclerosis, would be particu-
larly helpful. Such strategies include cascade testing of relatives from 
identified index cases [27], and universal screening for high cholesterol 
in children, which would enable identification of parents with FH [28]. 
Our study provides confirmatory evidence of higher excess CVD 
morbidity in younger age groups of patients with FH and, importantly, 
provides novel insight into gender differences in the diagnosis and 
management of FH, as well as substantial gender disparities in the excess 
cardiovascular disease burden associated with FH. The finding that 
excess CVD morbidity is markedly higher in women than men in the 
30–50 year age group, and also in those over 50 years, emphasizes the 
importance of early initiation of high intensity lipid-lowering treatment 
and highlights the need for optimisation of lipid-lowering and risk factor 
management for all FH patients with particular attention to women with 
FH. 
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